2KNOSP E, STEINER E, KITZ K, et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings [J]. Neurosurgery, 1993, 33(4): 610-618.
3VIEIRA J O JR, CUKIERT A, LIBERMAN B. Magnetic resonance imaging of cavernous sinus invasion by pituitary adenoma diagnostic criteria and surgical findings [J]. Arq Neuropsiquiatr, 2004, 62(2): 437-443.
4YU R, MELMED S. Oncogenc activation in pituitary tumors [J]. Brain Pathol, 2001, 11(3): 328-341.
5ZHANG X, HORWITZ G A, HEANEY A P, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas [J]. J Clin Endocrinol Metab, 1999, 84(2): 761-767.
6TFELT-HANSEN J, KANUPARTHI D, CHATTOPADHYAY N. The emerging role of pituitary tumor transforming gene in tumorigenesis [J]. Clin Med Res, 2006, 4(2): 130-137.
7GURLEK A, KARAVITAKI N, ANSORGE O, et al. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics [J]. Eur J Endocrinol, 2007, 156(2): 143-153.
8TROUILLAS J, DANIEL L, GUIGARD M P, et al. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion [J]. J Neurosurg, 2003, 98(5): 1084-1093.
9PAEZ-PEREDA M, KUCHENBAUER F, ARZT E, et al. Regulation of pituitary hormones and cell proliferation by components of the extracellular matrix [J]. Braz J Med Biol Res, 2005, 38(10): 1487-1494.
10MALIK M T, KAKAR S S. Regulation of angiogenesis and invasion by human pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2) [J]. Mol Cancer, 2006, 5(1): 61.
2Molitch ME, Thorner O, Wilson C. Mangement of prolactionmas. J Clin Endocrinol Metab, 1997,82:996-1006.
3Molitch ME. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am, 1999, 28:143-169.
4Grebe SK, Delahunt JW, Feek CM. Treatment of extensively invasive (giant) prolactinomas with bromocriptine. N Z Med J,1992,105:129-131.
5Sieck JO, Niles NL, Jinkins JR, et al. Extrasellar prolactinomas:successful management of 24 patients using bromocriptine. Horm Res, 1986,23:167-176.
6Van′t Verlaat JW, Croughs RJ, Hendriks MJ, et al. Results of primary treatment with bromccriptine of prolactinomas with extrasellar extension. Can J Neurol Sci, 1990,17 ;71-73.
7Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab, 1985,60:698-705.
8Bassetti M, Spada A, Pezzo G, et al. Bromocriptine treatment reduces the cell size in human macroprolactinomas:a morphometric study. J Clin Endocrinol Metab, 1984,58:268-273.
9Stefaneanu L, Kovacs K, Scheithauer BW, et al. Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocrine Pathol, 2000,11:341-352.
10Shrivatava RK, Arginteanu MS, King WA, et al. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg, 2002,97: 299 -306.
